| Literature DB >> 27882816 |
Abstract
There is a relative lack of long-term data for individual glucose-lowering therapies for the treatment of type 2 diabetes mellitus. A systematic search of published literature reporting data of approximately ≥3 years of follow-up from randomized controlled trials and their extensions was conducted. Trials to evaluate the efficacy and/or safety of glucose-lowering drugs currently approved for the treatment of adults with type 2 diabetes were included. Search results included long-term published data for traditional oral glucose-lowering drugs, insulin, α-glucosidase inhibitors, and incretin-based therapies. In general, results indicated that the short-term risk/benefit profile of these therapies is in line with longer-term evaluations. Individual results from these trials are reviewed in this report. These findings support the use of approved drug classes for longer-term treatment of type 2 diabetes.Entities:
Keywords: glucose-lowering therapies; incretin-based therapies; insulin; type 2 diabetes; α-Glucosidase inhibitors
Mesh:
Substances:
Year: 2016 PMID: 27882816 DOI: 10.1080/00325481.2017.1265417
Source DB: PubMed Journal: Postgrad Med ISSN: 0032-5481 Impact factor: 3.840